Drug
Prt2527
Prt2527: highest development phase Phase 1, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| PRT2527 NCT05665530 | Phase 1 | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) |
Latest
No recent events.
Follow Prt2527 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.